Concepedia

Author

Alison Laight

AstraZeneca (United Kingdom)

Also Known As

A Laight, A. Laight, Alison Laight

7

Publications

535

Citations

6

H-Index

23

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (Singapore)
AL

About

Alison Laight is an author at AstraZeneca (United Kingdom) specializing in pharmacotherapy, medicine, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

529

2

Pharmacology

6

6

529

3

Endocrinology

1

1

78

4

Obstetrics

1

1

78

5

Pathology

1

1

14

Alison Laight

×

6

Publications

529

Citations

6

H-Index

YearCitations

Pharmacokinetic Drug Interactions of Gefitinib with Rifampicin, Itraconazole and Metoprolol

Helen Swaisland, Malcolm Ranson, Robert P. Smith,

Clinical Pharmacokinetics

2005

155

Single-Dose Clinical Pharmacokinetic Studies of Gefitinib

Helen Swaisland, Robert P. Smith, Alison Laight,

Clinical Pharmacokinetics

2005

141

Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers

Helen Swaisland, Alison Laight, Lesley E. Stafford,

Clinical Pharmacokinetics

2001

118

A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers

Samuel B. Addo, R. A. Yates, Alison Laight

British Journal of Cancer

2002

78

564 Pharmacokinetics and metabolism of fulvestrant after oral, intravenous and intramuscular administration in healthy volunteers

M. Harrison, Alison Laight, Diana F. Clarke,

European Journal of Cancer Supplements

2003

23

EGF receptor tyrosine kinase inhibitors as anti-cancer agents - pre-clinical and early clinical profile of ZD 1839

J.R. Woodburn, Charles Morris, Hanna Kelly,

Cellular & Molecular Biology Letters

1998

14

Page 1